» 
Andrew Rice
Andrew Rice
A phoneA letter

Andrew Rice

Professor of pain research

Role in PharmNovo: Scientific advisor.

Hospital: Imperial College London.

Resumé: He received his medical degree from St. Mary’s Hospital Medical School (University of London) in 1982 and his research doctorate from St. Thomas’ Hospital Medical School (UMDS, University of London) in 1991. He underwent his specialist clinical training mainly in Oxford and at St Thomas’ Hospital. His research programme covers both laboratory and clinical research. The focus is on neuropathic pain in the context of infectious diseases, diabetic neuropathy and peripheral nerve trauma. The group is predominantly funded by grants from the Wellcome Trust, NC3Rs, European Commission and National Institute for Health Research.

In the clinical research domain: Andrew leads a programme of deep profiling studies mainly in patients with HIV neuropathy, carpal tunnel syndrome, leprosy and diabetic neuropathy. He has for many years been active in clinical trial design, conduct and interpretation and also in synthesising clinical evidence by means of meta-analyses. A recent success was his key role in the successful pre-clinical and early clinical development of the Angiotensin II type 2 receptor antagonist EMA401 as a “first in class” analgesic for neuropathic pain. He is a Councillor of the International Association for the Study of Pain (IASP) and he has held a number of positions on the Executive Committee of the International Association for the Study of Pain (IASP). He serves on the British Pain Society Council was a member of the Founding Board of the Faculty of Pain Medicine at the Royal College of Anaesthetists. He is an author of more than 160 scientific publications, many of which are in the major specialist journal in the field (PAIN).

Member of:

Latest news

View all
July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more